The company moved from the Main market to AIM on the 4th Feb 2019.
Circassia is a specialty pharmaceutical company focused on respiratory disease. Our growing commercial organization promotes our innovative asthma management products directly to specialist physicians in a number of key markets, and we market the chronic obstructive pulmonary disease (COPD) product Tudorza® in the United States. We are expanding our commercial platform in China, and are working to expand our portfolio through in-licensing, partnering or acquisition.
Our asthma management products
Our market-leading NIOX® products are used by specialists around the world to aid asthma diagnosis and management. We sell NIOX® direct in the United States, United Kingdom and Germany, and we are strengthening our presence in Europe and China. Our NIOX® products are also supplied in many other countries through our international network of partners.
Our US commercial collaboration
We collaborate with AstraZeneca in the United States, where we promote the COPD product Tudorza®. We also have the US commercial rights to Duaklir®*, for which AstraZeneca submitted a New Drug Application in Q2 2018. Both products feature the novel Pressair® device. As part of our collaboration we significantly expanded our US salesforce and strengthened our commercial team.
Our respiratory pipeline
Our lead asthma product targets substitution of GSK’s Flixotide® pMDI, and we have a product candidate targeting direct substitution of Seretide® pMDI. We also have a number of chronic obstructive pulmonary disease treatment candidates, including novel formulations of currently approved drugs and a substitute for Spiriva Handihaler®. We are seeking development partners for our pipeline products as part of our commercially-focused investment strategy.
Circassia was established in 2006, and in March 2014 we completed an initial public offering on the London Stock Exchange. In June 2015, we completed the acquisitions of Aerocrine and Prosonix as part of our strategy to independently commercialize our products and broaden our pipeline, and in April 2017 we established a commercial collaboration with AstraZeneca in the United States.
*The Duaklir® trademark is registered in the United States; the mark is not currently approved for use by the FDA.
Peel Hunt LLP
Peel Hunt LLP